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Regulated immune responses are essential to maintain intestinal homeostasis and require 
direct or indirect communication among cells. Communication that occurs among cells in 
the absence of direct contact is often through the use of cytokines and chemokines. 
Ulcerative colitis (UC) and Crohn's disease (CD) are chronic intestinal inflammatory bowel 
diseases (IBD). IBD is characterized by increased influx of immune cells to the mucosa of 
genetically susceptible hosts. The characteristic increase of inflammatory infiltrate is mainly 
of T cells recruited to the lamina propria (LP) by a multistep process that involves the 
integrated interactions and effects of adhesion molecules and chemokines (1). Numerous 
studies in IBD patients and in animal models of colitis have demonstrated that both 
inflammatory chemokines and their receptors are up-regulated in settings of active 
inflammation (2). More importantly, blockade or absence of various chemokine receptors 
attenuates disease in murine models of IBD. Thus, identifying chemokines and their 
receptors that are involved in intestinal inflammation provide promising targets for new 
drug development in the treatment of IBD. 
2. What is Chemokines?-Role in the pathogenesis of IBD- 
Chemokines have been implicated in many fundamental immune processes, including 
lymphoid organogenesis, immune cell differentiation, development and positioning (3) 
Chemokines are small 8-12kDa cytokines that can direct the recruitment and migration of 
circulating leukocytes and play a critical role in the differentiation of secondary lymphoid 
organs. There are approximately 50 known chemokines and 20 known receptors. 
Chemokines are classified in 4 separate families based on the pattern of their cysteine 
residues(C, CC, CXC and CX3C). The CC family of chemokines contains two adjacent 
cysteine residues. The CXC family has two cysteine residues separated by a non-cystein 
amino acid, whereas the CX3C family has two cysteine residues separated by three non-
cysteine amino acids. The C family has only one cysteine residue. Several reports on the 
relationship between IBD and chemokine have been reported. Here we will review several 
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chemokines that have been investigated in the context of IBD and finally described CXCL12-
CXCR4 axis including our data. 
3. CC family of chemokines 
3.1 CCL2 (MCP-1) and CCR2 
CCR2 and its ligands MCP-1,-2,-3 and -4 are involved in the recruitment of monocytes, 
dendritic cells, and memory T cells. In the intestine, MCP-1 is produced by intestinal 
epithelial cells. Mice deficient in MCP-1 are protected from hapten-induced colitis, as 
demonstrated by reduced hitological scores of colitis and lower IL-1┚, IL-12p40, and IFN-┛ 
(4). Furthermore, CCR2-deficient mice with dextran sulfate sodium (DSS)-induced colitis 
had lower histological scores than wild type mice (5). The chemokine receptor antagonist 
TAK-779, which blocks CCR2, CCR5, and CXCR3 could reduce colonic inflammation of 
DSS-induced colitis (6). These data suggested that CCR2 and its ligands seemed to play a 
crucial role in intestinal inflammation.  
3.2 CCL3 (MIP-1α), CCL4 (MIP-1β), CCL5 (RANTES) and CCR5 
Expression of CCL3 is up-regulated in the colon of rats exposed to TNBS  
and Administration of neutralizing antibodites to CCL3 blocked massive neutrophil 
influx (7). Expression of RANTES is induced by TNF-┙ and IFN-┛ and, together with its 
receptors CCR1 and CCR5, is up-regulated in the chronic phase of TNBS-induced colitis 
in rats (8).   
Interestingly, RANTES was specifically expressed in non-caseating granulomas of CD 
patients by in situ hybridization with surrounding CD4+ T cells expressing the CCR5 ad 
CXCR3 receptors. CCR5 and its ligands are involved in the migration of T cells and 
monocytes (9). CCL5-deficient mice are less susceptible to DSS-induced colitis and the 
inflammation that appears in CCR5-deficient mice is characterized by increased CD4+T cell 
and NK1.1+ cell influx together with an up-regulation of the Th2 cytokines IL-4, IL-5 and IL-
10 (4).  
3.3 CCL20 and CCR6 
CCL20 mediates chemotaxis of T cells, B cells and DCs (3). In the intestine, CCL20 is 
produced from IECs. In human IBD, CCL20 protien and RNA expression was increased in 
intestinal tissues of patients with CD but not those with UC. CCR6 deficient mice leads to 
decreased susceptibility to DSS (10) and intravital microscopic analyses showed that CCR6 
blockade on T and B cells reduced their adherence to mucosal and submucosal 
microvessels in the course of DSS colitis. Recently, CCR6 has been identified as a key 
modulator of Th17 cell recruitment to the intestine (11). Taken together, these data may 
suggest that CCL20 and CCR6 have a chemotactic effect on T and B cells under 
inflammatory conditions in the colon.  
3.4 CCL25 (thymus-expressed chemokine, TECK) and CCR9 
CCL25 is constitutively expressed by thymic epithelial cells and IECs in the small 
intestine but not in the colon (12). CCL25 binds to the CCR9 expressed on T cells and 
IgA+ plasma cells. In the intestine, CCR9 is expressed by both ┙┚ and ┛├ CD8┙┙+ 
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intraepithelial lymphocytes (IELs) and these cells migrate towards CCL25. CCR9-
deficient mice have a remarkable reduction of ┛├ IELs and administration of neutralizing 
antibody against CCL25 to young mice leads to decreased ┙┚ and ┛├ CD8┙┙+ IELs, 
suggesting that CCL25-CCR9 pathway might be involved in the early stages of intestinal 
inflammation.  
4. CX3CL1 (fractalkine) and CX3CR1 
CX3CL1/fractalkine is a member of the CX3C chemokine family, which is expressed by 
epithelial cells and IECs (13). CX3CL1 can be up-regulated by TNF-┙, IL-1┚, LPS and IFN-┛. 
CX3CL1 can function as an endothelial adhesive determinant to recruit a sub-population of 
dendritic cells and macrophages that have high CX3CR1 expression. The association 
between CX3CL1 and pathogenesis of IBD remains controversial. However, Sans, et al. 
reported that circulating T cells and lamina propria T cells from active CD patients 
contained a higher proportion of CX3CR1+ cells than CD patients with inactive disease or 
healthy subjects (14).  
5. The CXC family of Chemokines  
5.1 CXCL5 (ENA-78) and CXCR2  
Epithelial cell-derived neutrophil-activating peptide(ENA)-78 is a potent neutrophil 
chemoattractant, which is produced from IECs and LPS, TNF-┙ and IL-1┚ stimulate its 
production. ENA-78 shares sequence homology with CXCL-8 (IL-8). Expression of ENA-78 
is induced in the colonic tissues of both patients with UC and CD (15, 16).  
5.2 CXCL8 (IL-8) 
IL-8 is also a neutrophil chemoattractant that is produced by macrophages, fibroblasts, 
epithelial cells, hepatocytes and endothelial cells (17). Up-regulation of IL-8 in the gut of 
both UC and CD was observed and IL-8 production appears to correlate with histological 
severity of disease (18). As well as ENA-78, IL-8 can bind CXCR2, although its affinity for 
the receptor is lower.  
6. CXCL12 (SDF-1) and CXCR4 
Among chemokines, CXC chemokine ligand (CXCL)12 (stromal cell-derived factor (SDF)-
1/pre-B-cell-growth-stimulating factor (PBSF)) is particularly intriguing because it has been 
shown definitively to be involved in various developmental processes including 
hematopoiesis (19,20). CXCL12 was first characterized as a pre-B-cell growth-stimulating 
factor and  and the primary physiologic receptor for CXCL12 is CXCR4, which also 
functions as an entry receptor for strains of HIV-1(21), The studies using mutant mice 
with targeted gene disruption have revealed that CXCL12 and CXCR4 are essential for B 
cell development and colonization of bone marrow by hematopoietic stem cells (HSCs) 
and myeloid lineage cells during ontogeny as well as blood vessel formation in 
gastrointestinal tract, cardiac ventricular septum formation, and cerebellar development 
(22, 23,24). Recently, it was reported that CXCL12-CXCR4 chemokine signaling is essential 
for the development of plasmacytoid dendritic cells (pDC), which could rapidly produces 
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a huge amount of type I IFN (┙, ┚) following microbial stimulation (25), This axis also 
play a crucial role in the development of natural killer (NK) cells, which are generated 
from hematopoietic stem cells and play vital roles in the innate immune response against 
viral infection (26). Thus, CXCL12-CXCR4 axis is widely involved in the development of 
immune cell. The concept of CXCL12 as being solely a constitutive chemokine was 
recently challenged by data from other groups that investigated immune-mediated 
inflammatory disorders and demonstrated its role in joint, lung, and liver inflammation 
(27, 28).  
Nanki et al. showed that CXCL12 is highly expressed in the synovium of RA patients in 
contrast to patients with OA, and that anti-CD40 stimulation enhanced CXCL12 production 
by cultured synoviocytes from RA patients (29). Those authors hypothesized that the CD40 
ligand (CD154) expressed on activated memory T cells may stimulate the production of 
CXCL12 by synoviocytes and increase the migration of T cells.  
Thus, CXCR4/SDF-1┙ and its ligand CXCL12 is an important chemokine/receptor pair in 
various diseases, but have received very little attention in IBD.  
7. How is CXCL12/CXCR4 axis involved in the pathophysiology of IBD? 
Mikami, et al. investigated the role of CXCL12/CXCR4 axis in patents with IBD by analysis 
of CXCR4 expression on peripheral T cells (30). They demonstrated that CXCR4 expression 
on peripheral T cells in patients with active UC was significantly higher than that in inactive 
UC and controls. Moreover, a significant correlation between CXCR4 expressions and 
disease activity in patients with UC was observed. Hosomi, et al focused on the role of 
immature plasma cells in the pathophysiology of IBD (31). They demonstrated that the 
proportion of immature plasma cells was correlated positively with clinical activities of UC 
and CD and expression of CXCR3 and CXCR4 of immature plasma cells in UC patients was 
significantly higher than in controls. In addition, Dotan, et al. reported that CXCR4 was 
expressed by intestinal epithelial cells (IECs) and lamima propria cells and CXCR4 positive 
cells are significantly increased in lamina propria of IBD (32). Moreover, recent report 
indicated that evaluation of CXCR4 expression on CD4 T cells by FACS analysis could be a 
biomarker of Leukocytapheresis with a leukocyte removal filter (Cellsoba; Asahi Medical, 
Tokyo, Japan) (33). These data strongly suggested that CXCR4 positive cells could be 
involved in the pathophysiology of IBD.  
As for expression of CXCL12 expressing cells in patients with IBD, Dotan et al. reported as 
follows: CXCL12 expression of normal intestinal mucosa was more limited to the surface 
epithelium, while the expression was enhanced and more diffuse in IBD mucosa (32). This 
up-regulation was specific to IBD mucosa, and did not occur in non-IBD inflammatory 
conditions. Moreover, in IBD, CXCL12 was significantly up-regulated in the inflamed 
compared to the non-inflamed epithelium and stronger expression of CXCL12 in intestinal 
tissues was observed in patients with UC than in those with CD. Thus, this expression was 
likely to be more specific in active UC patients than in CD patients,  
However, using CXCL12/GFP knock-in approach, Mikami, et al. revealed that CXCL12-
expressing cells were mainly observed in the perivascular sites of the normal colonic 
mucosa, suggesting that the CXCL12-expressing cells were morphologically considered to 
be pericytes (adjacent to the endothelial cell) but not epithelial cells (30). After DSS 
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administration, gene expression of CXCL12 was strongly induced in mice with DSS-
colitis, which was compatible to human IBD data reported by Dotan. In this regard, more 
investigation should be required to identify CXCL12 expressing cells in normal and 
pathogenic conditions of intestinal mucosa. However, the exact reason why  
CXCL12-CXCR4 signaling was specifically involved in the pathophysiology of UC 
remains unclear. 
8. Blockade of CXCL12-CXCR4 signaling as therapeutic target of IBD 
As mentioned above, this axis can be strongly involved in the pathophysiology of IBD, 
particularly, UC. Next question is whether or not blocking of CXCL12-CXCR4 axis can be a 
new therapy for IBD. Mikami, et al showed that the effect of CXCR4 antagonist (TF14016) 
on colitis in dextran sodium sulfate (DSS) and interleukin (IL)-10 knockout (KO) models 
(30). 
Firstly, they examined CXCR4 expression on peripheral blood cells and CXCL12 expression 
of colonic tissue in mice with DSS-induced colitis. As expected, CXCR4 expression of CD4 
positive cells was significantly increased after the start of DSS administration, compared 
with normal mice and gene expression of CXCL12 was also significantly higher in the 
colonic tissue of mice with DSS-induced colitis than that of normal mice. Next, they 
evaluated the effect of CXCR4 antagonist (TF14016) on DSS-induced colitis. TF14016 
clinically and histologically attenuated intestinal inflammation of DSS-induced colitis. 
Interestingly, immunohistochemical analysis revealed not only the improvement of colonic 
inflammation but also reduction of lymphoid aggregations. They also investigated the effect 
of TF 14016 on cytokine production from mesenteric lymph node cells. Surprisingly, TF 
14016 treatment reduced pro-inflammatory cytokine production such as TNF-┙ and IFN-┛ 
but did not alter IL-10 production.  
Why did not TF 14016 treatment affect IL-10 production? It should be noted that TF 14016 
administration did not alter the percentage of FOXP3+CD25+T cell. This data suggested that 
ameliorating action of TF 14016 on DSS-induced colitis is mainly due to its inhibitory effect 
of CD4+CD25- T cells with increased CXCR4 expression. TF 14016 treatment also 
ameliorated colonic inflammation of IL-10 KO mice.  
9. Conclusion 
CXCL12 and CXCR4 have a constitutive and inflammatory role in the intestinal mucosa. 
Several human and mouse data strongly suggested that CXCL12-CXCR4 axis play a crucial 
role in the pathophysiology of IBD, especially UC. Therefore, we hope that therapeutic 
manipulation of this signaling is considered in IBD therapy. 
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